The story of Viagra and its influence on the pharmaceutical sector presents a intricate question regarding its continued viability as an investment. Initially a phenomenal success, generating billions , generic competition has substantially eroded financial returns. While established pharmaceutical firms maintain patents on related therapies and in

The trajectory of companies tied to blockbuster drugs like Viagra presents a nuanced investment scenario . While the initial surge of copyright, fueled by Viagra's extraordinary popularity, generated substantial returns, the expiry in key territories has introduced considerable risk . Investors are now grappling with the effect of rival medications